Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

FEI Acquires VSG

By Drug Discovery Trends Editor | August 1, 2012

FEI, a leading instrumentation company providing imaging and analysis systems for research and industry, announced that it has acquired Visualization Sciences Group (VSG) of Bordeaux, France. VSG provides high-performance 3D visualization software products and tools to a range of markets, including oil & gas, geosciences, mining, life sciences, materials science and industrial inspection.

“VSG is an extension and acceleration of our strategy to provide complete imaging and visualization solutions to our customers,” said Don Kania, president and CEO of FEI. “Their products and development capabilities fit well with all of our target markets, especially in our higher-growth Natural Resources and Life Sciences businesses. Our customers are expressing an increasing demand for analysis of the data our imaging systems create. At the same time, FEI intends to continue to build upon VSG’s growing software business. We are impressed with VSG’s solutions, including state-of-the-art 3D rendering, an open application framework, object-oriented 3D libraries and very large 3D data management capabilities. The company has a strong management team and a talented group of employees.”

“Combining with FEI gives us added breadth and distribution capabilities to continue our growth,” commented Jean-Bernard Cazeaux, president and CEO of VSG. “We look forward to further contributing to FEI’s success in high-growth opportunities where we have a solid customer base, such as Life Sciences and Natural Resources, and to contributing our expertise to applications across all of FEI’s markets.”

The purchase price for the acquisition is EURO44.8 million or approximately $55 million. FEI funded the purchase with euros from its European operations which otherwise would be subject to U.S. taxation if repatriated. VSG had pro-forma revenue for the 12 months ended June 30, 2012 of approximately $19 million and has 88 employees. FEI expects the acquisition to have a neutral impact on GAAP earnings for the second half of 2012 and to be accretive in 2013.

Date: August 1, 2012
Source: FEI


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50